Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633020 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT02633020 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 28 participants.
The verdict
NCT02633020, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Protocol CELIM-RCD-002 is designed to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with type II refractory celiac disease (RCD-II), an in-situ small bowel T-cell lymphoma.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AMG 714
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-04-13 |
| Est. Completion | 2017-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633020
The ClinicalTrials.gov registry entry for NCT02633020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02633020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02633020 about?
NCT02633020 is a clinical study titled "Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease". Protocol CELIM-RCD-002 is designed to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with type II refractory celiac disease (RCD-II), an in-situ small bowel T-cell lymphoma.
What is the current status of trial NCT02633020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2016-04-13. Estimated completion is 2017-05-02.
What interventions are being tested in trial NCT02633020?
The interventions under investigation include: Placebo (BIOLOGICAL), AMG 714 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02633020?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.